A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Trial Profile

A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2018

At a glance

  • Drugs Ibrutinib (Primary) ; Ofatumumab
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms RESONATE
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 17 Jun 2018 Results (n=1238)of a pooled analysis from RESONATE, RESONATE-2 and HELIOS studies, presented at the 23rd Congress of the European Haematology Association.
    • 05 Jun 2018 Results of a pooled analysis from Resonate and Resonate-2 studies presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 12 Dec 2017 Results of the validated risk model for Overall survival in CLL patients from five randomised trials (HELIOS, RESONATE, Study 115, Study 116 and Study 119; n=1866) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top